更正：发现 SI 1/20 和 SI 1/22 作为 5-氟尿嘧啶和咪唑类血红素加氧酶 1 抑制剂的互为原药，可提高对 DU145 前列腺癌细胞的细胞毒性。

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2024-07-23 DOI:10.1002/cmdc.202400510

{"title":"更正：发现 SI 1/20 和 SI 1/22 作为 5-氟尿嘧啶和咪唑类血红素加氧酶 1 抑制剂的互为原药，可提高对 DU145 前列腺癌细胞的细胞毒性。","authors":"","doi":"10.1002/cmdc.202400510","DOIUrl":null,"url":null,"abstract":"The authors regret that the original version of our paper contained incorrect structures of the metabolites FdUMP/FdUTP/FUTP in Figure 2 (p. 3 of 11), since the L-ribose (wrong) instead of natural D-ribose (correct) was depicted. The correct version of Figure 2 is shown below. Similarly, the graphical abstract has been corrected accordingly.\n Figure 2. The design strategy of 5-FU/HO-1 inhibitor mutual prodrugs.The corrections made in this corrigendum do not affect the original conclusions. The authors apologize for any inconvenience that the errors may have caused.Graphical Abstract\n ","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"19 21","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202400510","citationCount":"0","resultStr":"{\"title\":\"CORRIGENDUM: Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells\",\"authors\":\"\",\"doi\":\"10.1002/cmdc.202400510\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The authors regret that the original version of our paper contained incorrect structures of the metabolites FdUMP/FdUTP/FUTP in Figure 2 (p. 3 of 11), since the L-ribose (wrong) instead of natural D-ribose (correct) was depicted. The correct version of Figure 2 is shown below. Similarly, the graphical abstract has been corrected accordingly.\\n Figure 2. The design strategy of 5-FU/HO-1 inhibitor mutual prodrugs.The corrections made in this corrigendum do not affect the original conclusions. The authors apologize for any inconvenience that the errors may have caused.Graphical Abstract\\n \",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\"19 21\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202400510\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202400510\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202400510","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

图 2（第 3 页，共 11 页）中代谢物 FdUMP/FdUTP/FUTP 的结构不正确，因为描绘的是 L-核糖（错误）而不是天然 D-核糖（正确），作者对此表示遗憾。图 2 的正确版本如下。同样，图解摘要也做了相应更正。图 2.5-FU/HO-1 抑制剂互作原药的设计策略。本更正中的改正并不影响原始结论。作者对这些错误可能造成的不便深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CORRIGENDUM: Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells

The authors regret that the original version of our paper contained incorrect structures of the metabolites FdUMP/FdUTP/FUTP in Figure 2 (p. 3 of 11), since the L-ribose (wrong) instead of natural D-ribose (correct) was depicted. The correct version of Figure 2 is shown below. Similarly, the graphical abstract has been corrected accordingly.

Figure 2. The design strategy of 5-FU/HO-1 inhibitor mutual prodrugs.

The corrections made in this corrigendum do not affect the original conclusions. The authors apologize for any inconvenience that the errors may have caused.

Graphical Abstract

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.